Artesunate for Injection / Artesunate Amivas

About Amivas

Amivas is a commercial-stage biopharmaceutical company established as a transatlantic joint venture to address critical shortages in severe malaria treatment. Its core achievement is the regulatory approval and global commercialization of intravenous Artesunate, which became essential after the discontinuation of quinidine gluconate in 2019. The company has successfully launched the first and only licensed severe malaria treatment in Europe and secured FDA approval in the US, positioning itself as a key supplier to hospitals worldwide. Its mission is to expand its role as a leader in providing critical medicines for life-threatening infectious diseases.

Therapeutic Areas